Posted by Michael Wonder on 01 Nov 2022
Vigil Neuroscience receives FDA fast track designation for VGL101 for the treatment of patients with ALSP
1 November 2022 - Vigil Neuroscience today announced that the US FDA has granted fast track designation to VGL101 for the treatment of patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.
VGL101, Vigil’s lead product candidate, is a monoclonal antibody TREM2 agonist currently being evaluated in a Phase 1 trial in healthy volunteers.
